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Abstract: An otherwise healthy 27-year-old woman presented with complaints of sudden 
painless blurred vision in the right eye for one week. On examination, visual acuity was 20/30 in 
the right eye and 20/20 in left eye. Fundus examination OS was normal, but OD demonstrated 
an elevated, opaque, yellowish parapapillary choroidal lesion with grayish membrane associated 
with minimal subretinal fluid, suggestive of a choroidal neovascular membrane in the center. 
B-scan ultrasonography revealed findings consistent with a choroidal osteoma. Fundus fluores-
cein angiography of the right eye revealed a relatively well defined area of hyperfluorescence 
that increased in size and intensity in the later phases, suggestive of active extrafoveal choroidal 
neovascular membrane. Optical coherence tomography confirmed the extrafoveal choroidal neo-
vascular membrane with subfoveal fluid. She was treated with intravitreal bevacizumab OD. At 
the two-week visit, vision OD improved to 20/20. Fluorescein angiography and optical coherence 
tomography revealed a resolved choroidal neovascular membrane. Intravitreal bevacizumab may 
be an effective alternative in the management of choroidal neovascular membrane secondary 
to choroidal osteoma.
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Introduction
The term ‘choroidal osteoma’ was coined by Gass in 1978 when he described four 
healthy young women with characteristic ophthalmoscopic findings of slightly elevated, 
  yellowish, juxtapapillary, choroidal tumor with sharp geographic borders.1 The major-
ity of patients with choroidal osteoma maintain good vision. In a follow-up study of 
36 patients, the probability of loss of visual acuity (20/200 or worse) was more than 
50% by 10 years.2 These tumors demonstrate evidence of bone formation in the   choroid, 
and are believed to be choristomatous in origin.3 Choroidal neovascularization is the 
most frequent cause of visual loss in choroidal osteoma, with more than half of patients 
expected to develop choroidal neovascularization.3,4
Case report
A 27-year-old female presented complaining of blurred vision in the right eye for 
one week. Her past ocular, medical, and family histories were noncontributory. 
On examination, her best-corrected visual acuity was 20/30 N6 in the right eye 
and 20/20 N6 in the left eye. Her intraocular pressure was 11 mmHg in the right 
eye and 13 mmHg in the left eye. Her anterior segment examination in both eyes 
and fundus   examination of the left eye were unremarkable. Ophthalmoscopic Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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examination in the right eye showed a yellowish lesion on 
the posterior pole of about 5 mm × 5 mm in size (Figure 1). 
It was smooth on the surface with slight elevation. In the 
center of the lesion, subretinal hemorrhage of a fine dot 
size was noted. Fundus fluorescein angiography showed 
early patchy hyperfluorescence with late staining of the 
lesion. In the center of the lesion, and about one disc 
diameter nasal to the foveal avascular zone, early lacy 
hyperfluorescence (Figure 2) leaking in the late phase 
was noted, indicative of classic choroidal neovascular 
membrane, while the left eye showed an angiogram within 
normal limits. There was also an area of blocked fluores-
cence corresponding to the hemorrhage seen clinically. 
The B-scan showed very high reflectivity on the surface, 
with shadowing behind because of the presence of calcium 
in the leion (Figure 2). Optical coherence tomography 
Figure  1  Fluorescein  angiography  and  optical  coherence  tomography  showing 
corresponding  location  of  choroidal  neovascular  membrane  associated  with 
osteoma in right eye.
Figure 2 Fluorescein angiography of right eye showing early lacy hyperfluorescence 
of choroidal neovascular membrane with later leakage, and B-scan (80 dB) showing 
corresponding shadowing due to osteoma.
Figure  3  Absence  of  subfoveal  fluid  on  optical  coherence  tomography  with 
regressed choroidal neovascular membrane.
Figure  4  Fluorescein  angiography  showing  regressed  choroidal  neovascular 
membrane  with  no  leakage  (early,  middle,  and  late  phase  in  the  clockwise 
direction).
confirmed a choroidal neovascular complex with subretinal 
fluid extending to the fovea (Figure 1). A diagnosis of 
osteoma with choroidal neovascular membrane was made. 
The patient underwent intravitreal bevacizumab injec-
tion (1.25 mg in 0.05 mL) for the choroidal neovascular 
membrane. It showed regression at one week follow-up, 
with resolution of subretinal hemorrhage and no fluid on 
optical coherence tomography (Figure 3) and no leakage 
on fluorescein angiography (Figure 4). The lesion remained 
stable at monthly follow-up at six months, with a final 
visual acuity of 20/20 N6 at the last visit. OCT maps are 
shown in Figure 5.
Discussion
Owing to lack of pigment in the tumor and atrophy of 
  overlying retinal pigment epithelium, laser photocoagulation 
has limited efficacy (25%) in the treatment of choroidal 
neovascularization secondary to choroidal osteoma.5 Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Figure 5 OCT maps comparison showing reduction in thickness.
Intravitreal bevacizumab is independent of the intrinsic 
pigmentation and has the advantage of sparing the overlying 
retina. Despite the patient having an extrafoveal choroidal 
neovascular membrane, we preferred intravitreal bevaci-
zumab over laser. Encouraged by the results of antivascular 
endothelial growth factor for choroidal neovascular mem-
brane in choroidal osteoma reported by Ahmadieh et al6 and 
Narayanan et al,7 we administered intravitreal bevacizumab 
and achieved complete regression of choroidal neovas-
cularization. Because the visual acuity was 20/30 with 
minimal subfoveal fluid, and there was concern regarding 
the possibility of extension of the choroidal neovascular 
membrane into the foveal region, we kept the patient under 
close follow-up during the   regression period.
There are case reports of treatment of choroidal 
neovascular membrane associated with choroidal osteomas 
with photodynamic therapy and ranibizumab with good 
efficacy, but cost effectiveness is a constraint, also the 
choroidal   neovascular membranes noted in the literature are 
on the edge of choroidal osteoma.8,9 Our case illustrates an 
atypical location of choroidal neovascularization secondary 
to a choroidal osteoma that was successfully treated with 
intravitreal bevacizumab which is a very cost-effective treat-
ment modality when compared with others.
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